GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Operating Margin %

AIM ImmunoTech (STU:HXB2) Operating Margin % : -21,403.33% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. AIM ImmunoTech's Operating Income for the three months ended in Dec. 2023 was €-12.84 Mil. AIM ImmunoTech's Revenue for the three months ended in Dec. 2023 was €0.06 Mil. Therefore, AIM ImmunoTech's Operating Margin % for the quarter that ended in Dec. 2023 was -21,403.33%.

Warning Sign:

AIM ImmunoTech Inc operating margin has been in a 5-year decline. The average rate of decline per year is -32.3%.

The historical rank and industry rank for AIM ImmunoTech's Operating Margin % or its related term are showing as below:

STU:HXB2' s Operating Margin % Range Over the Past 10 Years
Min: -15800.5   Med: -11106.86   Max: -2612.36
Current: -15800.5


STU:HXB2's Operating Margin % is ranked worse than
93.41% of 1032 companies
in the Biotechnology industry
Industry Median: -168.78 vs STU:HXB2: -15800.50

AIM ImmunoTech's 5-Year Average Operating Margin % Growth Rate was -32.30% per year.

AIM ImmunoTech's Operating Income for the three months ended in Dec. 2023 was €-12.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was €-29.54 Mil.


AIM ImmunoTech Operating Margin % Historical Data

The historical data trend for AIM ImmunoTech's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Operating Margin % Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8,888.10 -9,211.94 -12,686.55 -14,140.60 -15,820.00

AIM ImmunoTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,896.23 -8,721.74 -12,925.64 -17,774.42 -21,403.33

Competitive Comparison of AIM ImmunoTech's Operating Margin %

For the Biotechnology subindustry, AIM ImmunoTech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Operating Margin % distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Operating Margin % falls into.



AIM ImmunoTech Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

AIM ImmunoTech's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-29.267 / 0.185
=-15,820.00 %

AIM ImmunoTech's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-12.842 / 0.06
=-21,403.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM ImmunoTech  (STU:HXB2) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


AIM ImmunoTech Operating Margin % Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech (STU:HXB2) Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines